公开(公告)号：US11517615B2

公开(公告)日：2022-12-06

申请号：US16609784

申请日：2018-05-03

Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

Inventor： Shane Crotty ,  Jennifer Dan

IPC: A61K39/00 ,  A61K39/09 ,  A61P37/04 ,  A61P31/04 ,  A61K35/17 ,  G01N33/563 ,  G01N33/569

Abstract: Recurrent tonsillitis disease (RT) is a common indication for pediatric tonsillectomy, the most frequent childhood surgery. It is unknown why some children develop RT. The present disclosure demonstrates that RT tonsils exhibit significantly smaller germinal centers than non-RT tonsils, concomitant with a bias against Group A Streptococcus (GAS)-specific germinal center follicular helper CD4+ T cells (GC Tfh), and significantly reduced antibodies to the GAS virulence factor SpeA. The present disclosure also shows a significant immunogenetic component to this disease, with the identification of ‘at risk’ and ‘protective’ HLA alleles for RT. Finally, the present disclosure identifies a new cell type, granzyme B+GC Tfh cells, which are activated by SpeA, are significantly more abundant in RT GC Tfh cells, and have the capacity to kill B cells, thus, providing a window into the immunology and genetics of a classic childhood disease and identifies a new type of pathogenic T cell.

公开(公告)号：US20220347295A1

公开(公告)日：2022-11-03

申请号：US17838890

申请日：2022-06-13

Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

Inventor： Donald A. Harn ,  Rafaella Queiroz ,  Lisa Shollenberger ,  Emily-Joy Farrah Samli

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/104 ,  A61K39/12 ,  A61K9/00 ,  A61K9/06 ,  A61K39/02 ,  A61K39/145 ,  A61K39/29 ,  A61K47/42 ,  A61K39/012 ,  A61K39/108 ,  A61K39/112 ,  A61K39/04 ,  A61K39/05 ,  A61K39/08 ,  A61K39/085 ,  A61K39/09 ,  A61K39/102 ,  A61K39/15 ,  A61K39/155 ,  A61K39/17 ,  A61K39/215 ,  A61K39/255 ,  A61K39/265

Abstract: A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

公开(公告)号：US11471530B2

公开(公告)日：2022-10-18

申请号：US16389358

申请日：2019-04-19

Applicant: SNIPR Technologies Limited

Inventor： Jasper Clube

IPC: A61K39/00 ,  A61K39/38 ,  A61K39/02 ,  A61K39/09 ,  A61K39/085 ,  A61K39/10 ,  A61K39/08 ,  A61K39/102 ,  A61K39/118 ,  A61K39/395 ,  A61K35/15 ,  A61K35/17 ,  A61K31/7105 ,  A61P37/00 ,  A61P35/00

Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.

公开(公告)号：US20220296695A1

公开(公告)日：2022-09-22

申请号：US17312442

申请日：2019-12-17

Applicant: Chitrananda ABEYGUNAWARDANA ,  Yadong Adam CUI ,  Romulo FERRERO ,  Jian HE ,  Luwy MUSEY ,  Tanaz PETIGARA ,  Julie M. SKINNER ,  Merck Sharp & Dohme Corp.

Inventor： Chitrananda Abeygunawardana ,  Yadong Adam Cui ,  Romulo Ferrero ,  Jian He ,  Luwy Musey ,  Tanaz Petigara ,  Julie M. Skinner

IPC: A61K39/09 ,  A61K47/20 ,  A61P31/04 ,  A61P37/04

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

公开(公告)号：US20220233674A1

公开(公告)日：2022-07-28

申请号：US17614865

申请日：2020-06-01

Applicant: Merck Sharp & Dohme Corp.

Inventor： Jian He ,  Patrick McHugh ,  Katherine M. Phillips ,  Adriana N. Santiago-Miranda

IPC: A61K39/09 ,  A61K39/385 ,  A61P31/04

Abstract: The present invention provides a process improvement related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein. The serotype 35B polysaccharide-protein conjugate, prepared by the disclosed process, is, among other things, more immunogenic than similar conjugates made by prior art methods. S. pneumoniae serotype 35B polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccine compositions.

公开(公告)号：US20220218812A1

公开(公告)日：2022-07-14

申请号：US17614876

申请日：2020-06-01

Applicant: Merck Sharp & Dohme Corp.

Inventor： Jian He ,  Robin M. Kaufhold ,  Julie M. Skinner ,  Jinfu Xie

IPC: A61K39/09 ,  A61P31/04 ,  A61K47/64

Abstract: The present invention provides methods for treating patients by administering an immunogenic multivalent pneumococcal polysaccharide-protein conjugate vaccine which comprises a S. pneumoniae serotype 35B polysaccharide-protein conjugate, does not comprise a S. pneumoniae serotype 29 polysaccharide-protein conjugate, and provides protection against S. pneumoniae serotype 29.

公开(公告)号：US11384339B2

公开(公告)日：2022-07-12

申请号：US16694748

申请日：2019-11-25

Applicant: Wisconsin Alumni Research Foundation (WARF)

Inventor： Yoshihiro Kawaoka ,  Gabriele Neumann ,  Makoto Ozawa

IPC: C12N7/00 ,  A61K39/145 ,  A61K39/12 ,  A61K35/76 ,  A61K39/09 ,  G01N33/569 ,  A61K39/00

Abstract: The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.

公开(公告)号：US20220184199A1

公开(公告)日：2022-06-16

申请号：US17601949

申请日：2020-04-06

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Isis Kanevsky ,  Farid Latif Khan ,  Charles Harold Jones ,  John Michael McLaughlin

IPC: A61K39/09

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20220143167A1

公开(公告)日：2022-05-12

申请号：US17347435

申请日：2021-06-14

Applicant: Pogona, LLC

Inventor： Bruce D. Forrest ,  Jack D. Love

IPC: A61K39/09 ,  A61P31/04

Abstract: Saccharide-polypeptide conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are disclosed.

公开(公告)号：US20220110330A1

公开(公告)日：2022-04-14

申请号：US17457806

申请日：2021-12-06

Applicant: QUORUM INNOVATIONS, LLC

Inventor： EVA A. BERKES ,  NICHOLAS T. MONSUL ,  FREDERICK T. BOEHM

IPC: A01N63/20 ,  A61K35/644 ,  A61K35/744 ,  A61K8/67 ,  A61Q11/00 ,  A61Q17/00 ,  A61K8/98 ,  A61K8/99 ,  A61K35/74 ,  A61K39/09 ,  A61K45/06 ,  A61K9/00 ,  A61K35/747 ,  A61Q19/10 ,  C12N1/20 ,  C12Q1/04 ,  A61Q19/00 ,  C12Q1/18 ,  A61K8/34 ,  A61K47/10

Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.